Merck & Co. reported $66.6B of revenue over the trailing twelve months, +4.6% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $66.6B (to Q2 2026). Net income: $3.17B, trailing twelve months to Q2 2026. Free cash flow: $16.1B, trailing twelve months to Q2 2026. EPS: $1.26, trailing twelve months to Q2 2026.

MRKMerck & Co.

Healthcare

$145.57+83% 1Y

$145.57

$75.8352 weeks$156.44

MRK as reported

Merck & Co. reported $66.6B of revenue over the trailing twelve months, +4.6% on the year before. 9 reported series are charted on this page, each one as filed.

$66.6B

Revenue, trailing twelve months · to Q2 2026 · +4.6% against the twelve months before

Net income: $3.17B
Net income · −81% year on year · trailing twelve months to Q2 2026
Free cash flow: $16.1B
Free cash flow · +9.1% year on year · trailing twelve months to Q2 2026
EPS: $1.26
EPS · −81% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for MRK, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$66.6B	+4.6%	Q2 2026
Net income	$3.17B	−81%	Q2 2026
EPS	$1.26	−81%	Q2 2026
Gross margin	73%	n/a	Q2 2026
Net margin	4.4%	n/a	Q2 2026
ROE	25%	n/a	Q2 2026
ROA	9.4%	n/a	Q2 2026
Free cash flow	$16.1B	+9.1%	Q2 2026
P/E	116	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.